Orforglipron
Also known as: LY3502970, OWL833
Orforglipron is an oral non-peptide GLP-1 receptor agonist developed by Eli Lilly, representing a breakthrough in weight management and type 2 diabetes treatment by enabling once-daily oral dosing of a small molecule that mimics incretin hormone activity.
Key Findings at a Glance
- •Orforglipron is the first oral non-peptide small molecule GLP-1 receptor agonist to reach Phase 3 clinical trials, eliminating the need for injections required by all currently approved GLP-1 therapies.
- •In the ATTAIN-1 Phase 3 trial, the 36 mg dose produced 11.2 percent mean body weight reduction at 72 weeks in adults with obesity, with 54.6 percent of participants achieving at least 10 percent weight loss.
- •The ACHIEVE-1 trial demonstrated HbA1c reductions of 1.48 percentage points with orforglipron 36 mg in early type 2 diabetes, significantly exceeding placebo at 40 weeks.
- •Unlike oral semaglutide which requires fasting and limited water intake for absorption, orforglipron can be taken as a daily tablet without dietary restrictions due to its non-peptide small molecule structure.
Orforglipron Overview & Molecular Profile
Orforglipron is a first-in-class oral non-peptide small molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor, developed by Eli Lilly. Unlike traditional GLP-1 receptor agonists such as semaglutide and liraglutide that are peptide-based and require injection, orforglipron is a small molecule that can be taken as a daily oral tablet without the dietary restrictions associated with oral semaglutide (Rybelsus). The compound was identified through high-throughput screening and medicinal chemistry optimization, resulting in a molecule with high selectivity and potency at the GLP-1 receptor. Orforglipron has progressed through Phase 2 and Phase 3 clinical trials including the ACHIEVE and ATTAIN programs, demonstrating significant efficacy in both glycemic control and weight reduction. Its oral bioavailability and lack of peptide-related absorption limitations position it as a potentially transformative therapy in the metabolic disease landscape.
Mechanism of Action: Receptor Agonism & Metabolic Pathways
Orforglipron acts as a full agonist at the GLP-1 receptor, a G protein-coupled receptor expressed in pancreatic beta cells, the gastrointestinal tract, and the central nervous system. Upon binding, it stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriate glucagon release from alpha cells, slows gastric emptying to reduce postprandial glucose excursions, and activates hypothalamic satiety centers to reduce appetite and food intake. Unlike peptide-based GLP-1 receptor agonists, orforglipron achieves receptor activation through a distinct binding mode as a small molecule, conferring resistance to proteolytic degradation in the gastrointestinal tract and enabling reliable oral absorption without the need for absorption enhancers or specific dosing conditions. The compound demonstrates biased agonism at the GLP-1 receptor, preferentially activating G protein signaling pathways over beta-arrestin recruitment, which may contribute to its favorable efficacy and tolerability profile.
Research-Observed Effects
Weight Reduction
Phase 3 clinical trials in the ATTAIN program have demonstrated significant dose-dependent weight loss with orforglipron in adults with obesity or overweight. In the ATTAIN-1 trial, the 36 mg dose produced mean body weight reductions of approximately 11.2% compared to 2.1% with placebo at 72 weeks, with 54.6% of participants achieving at least 10% weight loss. The weight reduction is mediated through central appetite suppression via hypothalamic GLP-1 receptor activation and peripheral effects including delayed gastric emptying. These results position orforglipron as a competitive oral alternative to injectable GLP-1 receptor agonists for chronic weight management, with the convenience advantage of once-daily oral dosing without meal-timing restrictions.
Glycemic Control
The ACHIEVE-1 Phase 3 trial demonstrated robust glycemic improvements in adults with early type 2 diabetes managed with diet and exercise alone. The 36 mg dose reduced HbA1c by 1.48 percentage points compared to 0.41 with placebo at 40 weeks, achieving statistical significance. Orforglipron's glucose-lowering effects are mediated through glucose-dependent insulin secretion, glucagon suppression, and delayed gastric emptying, mirroring the mechanisms of injectable GLP-1 receptor agonists. The oral formulation provides a significant practical advantage for patients who may be reluctant to initiate injectable therapy early in their diabetes management journey.
Cardiometabolic Improvement
Clinical trials have documented improvements in multiple cardiometabolic risk markers beyond glycemic control and weight loss. Orforglipron treatment has been associated with reductions in systolic blood pressure, improvements in lipid profiles including reductions in triglycerides and increases in HDL cholesterol, and decreases in waist circumference. These pleiotropic cardiometabolic benefits are consistent with the class effects observed with other GLP-1 receptor agonists and likely reflect both direct receptor-mediated effects and indirect benefits of weight reduction. Ongoing cardiovascular outcomes trials will determine whether these surrogate marker improvements translate into reduced major adverse cardiovascular events.
Appetite Suppression
Orforglipron produces sustained reduction in appetite and caloric intake through activation of GLP-1 receptors in the hypothalamus and brainstem appetite-regulating centers. Clinical trial participants report reduced hunger, increased satiety, and decreased food cravings, contributing to the observed weight loss outcomes. The appetite-suppressive effects appear to be maintained throughout long-term treatment without significant tachyphylaxis. Studies using food intake assessments have documented reductions in ad libitum energy intake of approximately 25-30% compared to pre-treatment baseline, consistent with the magnitude of weight loss observed in clinical trials.
Beta Cell Function Preservation
Preclinical and early clinical data suggest orforglipron may have protective effects on pancreatic beta cell function beyond acute glucose-dependent insulin secretion. GLP-1 receptor activation has been shown to promote beta cell proliferation, inhibit apoptosis, and enhance insulin gene transcription in animal models. Clinical measures of beta cell function including HOMA-B and proinsulin-to-insulin ratios have shown improvement with orforglipron treatment in Phase 2 trials. These findings are consistent with the established beta cell trophic effects of the GLP-1 receptor agonist class, though long-term preservation of beta cell mass in humans remains to be definitively demonstrated.
Research Dosing Information
In Phase 3 clinical trials, orforglipron was administered as a once-daily oral tablet with dose escalation from 3 mg to target doses of 12, 24, or 36 mg. The dose titration schedule was designed to improve gastrointestinal tolerability. Unlike oral semaglutide, orforglipron does not require fasting conditions or specific water volume restrictions for dosing.
Note: Dosing information is provided for research reference only and is based on published studies using research subjects. This is not a recommendation for any use.
Research Studies & References
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Wharton S, Blevins T, Connery L, et al. (2023). New England Journal of Medicine
This Phase 2, double-blind, randomized, placebo-controlled trial evaluated the efficacy and safety of orforglipron in 272 adults with obesity or overweight with at least one weight-related comorbidity but without diabetes. Participants were randomized to one of four orforglipron doses (12, 24, 36, or 45 mg daily) or placebo for 36 weeks. The primary endpoint was percentage change in body weight from baseline. At 36 weeks, orforglipron produced dose-dependent weight loss ranging from 8.6% to 12.6% compared to 2.0% with placebo, with the 36 mg dose demonstrating 9.4% placebo-adjusted weight reduction. The proportion of participants achieving at least 10% weight loss ranged from 46% to 75% across orforglipron doses compared to 9% with placebo. Gastrointestinal adverse events including nausea, vomiting, and diarrhea were the most commonly reported side effects and were generally mild to moderate in severity. These results provided the first evidence that an oral non-peptide GLP-1 receptor agonist could achieve clinically meaningful weight loss comparable to injectable therapies.
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Rosenstock J, Frias JP, Rodbard HW, et al. (2025). New England Journal of Medicine
The ACHIEVE-1 Phase 3 trial was a randomized, double-blind, placebo-controlled study evaluating orforglipron in adults with early type 2 diabetes managed with diet and exercise alone. Participants were randomized to receive oral orforglipron at escalating doses up to 36 mg daily or matching placebo. The primary endpoint was change in HbA1c from baseline at 40 weeks. The 36 mg orforglipron dose produced a reduction in HbA1c of 1.48 percentage points compared to 0.41 percentage points with placebo, achieving highly significant superiority. Clinically meaningful proportions of participants achieved HbA1c targets below 7.0% and below 6.5%, with corresponding body weight reductions. The safety profile was consistent with the GLP-1 receptor agonist class, with gastrointestinal events being the most common adverse effects. This trial established orforglipron as an effective oral option for glycemic control in early type 2 diabetes.
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
Aronne LJ, Sattar N, Horn DB, et al. (2025). New England Journal of Medicine
The ATTAIN-1 Phase 3 trial evaluated the efficacy and safety of orforglipron for the treatment of obesity in adults without diabetes. This randomized, double-blind, placebo-controlled trial enrolled participants with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity. Orforglipron at the 36 mg dose produced mean body weight reductions of 11.2% at 72 weeks compared to 2.1% with placebo, representing a treatment difference of 9.1 percentage points. Approximately 54.6% of participants in the 36 mg group achieved at least 10% body weight loss compared to a substantially smaller proportion with placebo. Improvements in cardiometabolic parameters including waist circumference, blood pressure, and lipid levels were also observed. The study confirmed the long-term efficacy and tolerability of orforglipron as the first oral non-peptide GLP-1 receptor agonist to demonstrate significant weight loss in a Phase 3 obesity trial.
Frequently Asked Questions
Semaglutide (GLP-1)
C187H291N45O59
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist that mimics the incretin hormone GLP-1, regulating blood glucose levels, appetite, and body weight through multiple metabolic pathways.
Liraglutide (GLP-1)
C172H265N43O51
Liraglutide is a GLP-1 receptor agonist with 97% amino acid sequence homology to native GLP-1, modified with a palmitic acid chain for extended duration of action, used in research for diabetes and obesity.
Tirzepatide (GLP-1/GIP)
C225H348N48O68
Tirzepatide is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist, providing synergistic metabolic effects for diabetes and obesity research.